Janney Montgomery Scott Initiates Coverage on Supernus Pharmaceuticals, Inc. (SUPN)

Janney Montgomery Scott assumed coverage on shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in a research report issued to clients and investors on Friday, July 14th, MarketBeat Ratings reports. The firm set a “neutral” rating and a $47.00 price target on the specialty pharmaceutical company’s stock. Janney Montgomery Scott’s target price points to a potential upside of 12.71% from the company’s current price.

Several other analysts also recently commented on the stock. Cantor Fitzgerald upped their price objective on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the company a “buy” rating in a report on Wednesday, July 5th. Stifel Nicolaus upped their price objective on shares of Supernus Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, April 3rd. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a report on Thursday, July 13th. Jefferies Group LLC set a $35.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 10th. Finally, BidaskClub raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Supernus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $48.43.

Shares of Supernus Pharmaceuticals (SUPN) traded down 0.95% on Friday, hitting $41.70. 358,778 shares of the stock traded hands. Supernus Pharmaceuticals has a one year low of $17.25 and a one year high of $44.95. The stock has a 50 day moving average of $42.46 and a 200 day moving average of $33.49. The company has a market cap of $2.11 billion, a PE ratio of 21.05 and a beta of 1.31.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.24 by $0.08. The business had revenue of $75.83 million for the quarter, compared to the consensus estimate of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. Equities analysts anticipate that Supernus Pharmaceuticals will post $1.00 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Janney Montgomery Scott Initiates Coverage on Supernus Pharmaceuticals, Inc. (SUPN)” was originally reported by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.themarketsdaily.com/2017/08/08/supernus-pharmaceuticals-inc-supn-now-covered-by-analysts-at-janney-montgomery-scott-updated-updated-updated.html.

In related news, VP Padmanabh P. Bhatt sold 3,735 shares of the firm’s stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $44.90, for a total transaction of $167,701.50. Following the completion of the sale, the vice president now directly owns 21,209 shares in the company, valued at $952,284.10. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 5,500 shares of the firm’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $34.90, for a total transaction of $191,950.00. Following the sale, the vice president now owns 43,887 shares of the company’s stock, valued at $1,531,656.30. The disclosure for this sale can be found here. Insiders sold 24,291 shares of company stock valued at $962,766 over the last quarter. Company insiders own 6.70% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in SUPN. Meeder Asset Management Inc. raised its position in shares of Supernus Pharmaceuticals by 3,455.2% in the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 2,315 shares during the period. Ameritas Investment Partners Inc. bought a new position in shares of Supernus Pharmaceuticals during the first quarter valued at $127,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Supernus Pharmaceuticals by 278.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 2,220 shares during the period. Victory Capital Management Inc. raised its position in shares of Supernus Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock valued at $148,000 after buying an additional 517 shares during the period. Finally, Fortaleza Asset Management Inc. bought a new position in shares of Supernus Pharmaceuticals during the first quarter valued at $160,000. 94.39% of the stock is owned by institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply